Market capitalization

PLATINUM EQUITY INVESTS IN TAK COMMUNICATIONS

Retrieved on: 
Friday, March 22, 2024
Platinum Equity, Growth, Communication, Market capitalization, Internet, Ingram Micro, LOS, Telecommunications, Platinum

LOS ANGELES, March 22, 2024 /PRNewswire/ -- Platinum Equity announced today a significant investment in TAK Communications, a national provider of communications and broadband infrastructure services. Financial terms were not disclosed.

Key Points: 
  • Firm to partner with TAK's current shareholders and management team, which will continue as equity partners in the business
    LOS ANGELES, March 22, 2024 /PRNewswire/ -- Platinum Equity announced today a significant investment in TAK Communications, a national provider of communications and broadband infrastructure services.
  • Headquartered in Sioux Falls, South Dakota, TAK provides fiber and broadband network services, last-mile connectivity and on-premises technology deployment solutions for the broadband and telecommunications industries.
  • "TAK has built an impressive business with national scale that today provides full end-to-end capabilities across the network deployment value chain," said Platinum Equity Co-President Jacob Kotzubei.
  • "The broadband communications services space is highly fragmented, and TAK has significant room to grow both organically and through additional acquisitions," said Platinum Equity Managing Director Dan Krasner.

Medivir to present at Swiss Nordic Bio in Zürich on March 7

Retrieved on: 
Wednesday, March 6, 2024
Market capitalization, Nasdaq Stockholm, Acceleration, Drug development, Trial of the century, Liver cancer, Patient, Cancer, Partnership, Pharmaceutical industry

CEO Jens Lindberg will present Medivir with focus on data from the ongoing phase 1b/2a clinical study with fostroxacitabine bralpamide (fostrox) and how these data enable an acceleration of fostrox's development program.

Key Points: 
  • CEO Jens Lindberg will present Medivir with focus on data from the ongoing phase 1b/2a clinical study with fostroxacitabine bralpamide (fostrox) and how these data enable an acceleration of fostrox's development program.
  • Swiss Nordic Bio aims to bring together biotech, pharma and life science investors from Switzerland and the Nordic region.
  • In addition to the presentation, the company will also conduct a number of 1-1 meetings with potential investors and partners.
  • Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership.

Medivir to present at the Life Science Day in Gothenburg on March 6

Retrieved on: 
Monday, March 4, 2024
Nasdaq Stockholm, Drug development, Liver cancer, Conference, Patient, Acceleration, Market capitalization, Sahlgrenska University Hospital, Cancer, Partnership, Pharmaceutical industry

CEO Jens Lindberg will present Medivir with focus on data from the ongoing Phase 1b/2a clinical trial with fostroxacitabine bralpamide (fostrox) and how these data enable an acceleration of fostrox's development program.

Key Points: 
  • CEO Jens Lindberg will present Medivir with focus on data from the ongoing Phase 1b/2a clinical trial with fostroxacitabine bralpamide (fostrox) and how these data enable an acceleration of fostrox's development program.
  • The Life Science Day in Gothenburg is arranged for the eighth time.
  • Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer and to minimize side effects.
  • Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership.

Mutual of America Financial Group Names Thaddeus Pollock as Executive Vice President and Head of Value Equity

Retrieved on: 
Thursday, February 1, 2024
Certified Management Accountant, Growth, Lehman Brothers, Knowledge, Yale University, Research, Pollock, Mutual of America, FSA, Investment, Sound, Organization, Market capitalization, The Wall Street Journal, Chartered Financial Analyst, Financial adviser

NEW YORK, Feb. 1, 2024 /PRNewswire/ -- Mutual of America Financial Group , which specializes in providing retirement services and investments to organizations and individuals, is pleased to announce that Thaddeus Pollock has joined Mutual of America Capital Management LLC as Executive Vice President and Head of Value Equity.

Key Points: 
  • NEW YORK, Feb. 1, 2024 /PRNewswire/ -- Mutual of America Financial Group , which specializes in providing retirement services and investments to organizations and individuals, is pleased to announce that Thaddeus Pollock has joined Mutual of America Capital Management LLC as Executive Vice President and Head of Value Equity.
  • Pollock is responsible for managing the Small Cap and Mid Cap Value investment strategies.
  • In this role, he will oversee all aspects of the Value Equity portfolio management within MoA Funds and separately managed accounts, which, combined, have approximately $28 billion in assets.
  • He reports directly to Stephen Rich, Chairman and CEO of Mutual of America Capital Management LLC.

Medivir to present at the Redeye Fight Cancer Day

Retrieved on: 
Wednesday, January 24, 2024
Nasdaq Stockholm, Market capitalization, Partnership, Patient, Drug development, Trial of the century, Liver cancer, Cancer, Medivir, Pharmaceutical industry

STOCKHOLM, Jan. 24, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Fight Cancer Day, today January 24, 2024.

Key Points: 
  • STOCKHOLM, Jan. 24, 2024 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Fight Cancer Day, today January 24, 2024.
  • CEO Jens Lindberg will present the company and updated data from the ongoing phase 1b/2a clinical study with fostroxacitabine bralpamide (fostrox) at 15.20 CET.
  • Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high.
  • Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer and to minimize side effects.

AtriCure Releases 2023 ESG Report

Retrieved on: 
Tuesday, November 14, 2023
Other Science, Medical Supplies, FDA, Research, DEI (Diversity, Equity and Inclusion), Other Health, Surgery, Consumer, Environmental, Social and Governance (ESG), Medical Devices, Hospitals, Genetics, Clinical Trials, Professional Services, Cardiology, Biotechnology, Alternative Medicine, Health, Science, Other Consumer, Disclosure, Woman, Social, Emotional intelligence, Corporation, LAA, Sustainability accounting, USB On-The-Go, Student, Patient, Sustainability Accounting Standards Board, ISR, Equity, National Association, Heart, Electrophysiology, Atrial fibrillation, NACD, Public company, Supply, Education, Diversity, Elective surgery, Market capitalization, Inappropriate sinus tachycardia, ESG, Pharmaceutical industry, Nursing

“At AtriCure, our focus on making a positive difference for patients is at the heart of our ESG strategy,” said Michael Carrel, President and Chief Executive Officer at AtriCure.

Key Points: 
  • “At AtriCure, our focus on making a positive difference for patients is at the heart of our ESG strategy,” said Michael Carrel, President and Chief Executive Officer at AtriCure.
  • We are committed to further advancing our ESG programs and improving transparency on our focus areas in the years ahead.”
    Key accomplishments detailed in AtriCure’s 2023 ESG Report include:
    Receiving recognition for Diversity, Equity & Inclusion from the National Association of Corporate Directors (NACD).
  • AtriCure’s 2023 ESG Report aims to address the company’s diverse stakeholders who are interested in ESG-related information, including investors, customers, employees, communities, suppliers, and patients.
  • Please visit the “Corporate Responsibility” section under “About AtriCure” of the company’s website at www.atricure.com/esg to view the report.

Medivir to present at the Carlsquare Equity Research Investor Day

Retrieved on: 
Wednesday, December 6, 2023
Nasdaq Stockholm, Drug development, Patient, Partnership, Market capitalization, Cancer, SMAC, Medivir

STOCKHOLM, Dec. 6, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Carlsquare Equity Research Investor Day, today December 6, 2023.

Key Points: 
  • STOCKHOLM, Dec. 6, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Carlsquare Equity Research Investor Day, today December 6, 2023.
  • CEO Jens Lindberg will present at 14.30 CET, with focus on the latest developments and the company's future plans.
  • Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.
  • Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership.

Medivir to present at the Redeye Life Science Day

Retrieved on: 
Wednesday, November 22, 2023
Nasdaq Stockholm, Drug development, CET, Patient, Partnership, Market capitalization, Cancer, Red eye, SMAC, Pharmaceutical industry, Medivir

STOCKHOLM, Nov. 22, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Life Science Day, tomorrow November 23, 2023.

Key Points: 
  • STOCKHOLM, Nov. 22, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Life Science Day, tomorrow November 23, 2023.
  • CEO Jens Lindberg will participate in an In Focus interview at 13.20 CET, led by Redeye analyst Richard Ramanius, with focus on the latest developments and the company's future plans.
  • Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a pro-drug designed to selectively treat liver cancer cells and to minimize side effects.
  • Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership.

BEST Inc. Receives Notice Regarding NYSE Continued Listing Standards

Retrieved on: 
Tuesday, November 14, 2023
NYSE, Culture, NYSE Listed Company Manual, Ecosystem, Annual report, American depositary receipt, Criterion, Letter, Market capitalization, BEST

The Company is currently in compliance with all other NYSE continued listing standards, and the Company's American Depositary Shares will continue to be listed and traded on the NYSE.

Key Points: 
  • The Company is currently in compliance with all other NYSE continued listing standards, and the Company's American Depositary Shares will continue to be listed and traded on the NYSE.
  • The business plan will then be reviewed by the NYSE.
  • If the plan is accepted, the Company will be subject to quarterly monitoring for compliance with the plan.
  • Further information regarding these and other risks is included in BEST's filings with the SEC.

Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors

Retrieved on: 
Thursday, November 9, 2023
Atossa, Doctor of Philosophy, Lindner, Computational biology, Drug development, Growth, Medicine, Market capitalization, Breast cancer, Partner, CFA, Therapy, Chemistry, Pharmaceutical industry, MD

Mr. Finn has more than 25 years of experience in the financial industry with a focus on early to mid-stage biotech and technology companies.

Key Points: 
  • Mr. Finn has more than 25 years of experience in the financial industry with a focus on early to mid-stage biotech and technology companies.
  • Mr. Finn currently serves as Executive Vice President and Chief Investment Officer at Vantage Consulting Group, an investment advisory firm.
  • In this role, he directs investment strategy, asset allocation, manager selection and portfolio construction.
  • “We are pleased to welcome Jon, who has extensive experience working with clinical stage biotechnology companies to accelerate growth and commercialize assets, to our board of directors,” said Steven Quay, MD, PhD, Atossa’s President and Chief Executive Officer.